Analysts See $-0.11 EPS for Applied DNA Sciences Inc (APDN)

November 21, 2017 - By Louis Casey

 Analysts See $ 0.11 EPS for Applied DNA Sciences Inc (APDN)
Investors sentiment decreased to 0.73 in Q2 2017. Its down 0.65, from 1.38 in 2017Q1. It is negative, as 4 investors sold Applied DNA Sciences Inc shares while 7 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.49 million shares or 25.31% less from 3.33 million shares in 2017Q1 were reported.
Geneva Advsr Ltd Llc owns 35,196 shares. Wells Fargo And Mn holds 0% or 1,108 shares in its portfolio. Bancorporation Of Montreal Can invested 0% in Applied DNA Sciences Inc (NASDAQ:APDN). Geode Cap Limited Co has invested 0% of its portfolio in Applied DNA Sciences Inc (NASDAQ:APDN). Gluskin Sheff And Assoc invested in 20,000 shares. Morgan Stanley has 112,834 shares. The New York-based Blackrock has invested 0% in Applied DNA Sciences Inc (NASDAQ:APDN). Mcf Advsrs Ltd reported 0% in Applied DNA Sciences Inc (NASDAQ:APDN). Reilly Fincl Advsr Ltd invested in 50,000 shares. Commonwealth Equity Services Inc reported 19,694 shares. Vanguard Group Inc has invested 0% in Applied DNA Sciences Inc (NASDAQ:APDN). National Bank Of New York Mellon accumulated 17,200 shares. Northern Trust, a Illinois-based fund reported 38,924 shares. Oppenheimer Co holds 0% or 13,527 shares. Citigroup reported 467 shares stake.

Investors wait Applied DNA Sciences Inc (NASDAQ:APDN) to report on December, 5. its quarterly earnings Wall Street analysts expect $-0.11 EPS, down $0.01 or 10.00 % from last year’s $-0.1 same quarter earnings. Applied DNA Sciences Inc’s Wall Street analysts see 10.00 % negative EPS growth, taking into account the $-0.10 EPS reproted in the previous quarter, About 13,300 shares traded. Applied DNA Sciences Inc (NASDAQ:APDN) has declined 49.09% since November 21, 2016 and is downtrending. It has underperformed by 65.79% the S&P500.

Applied DNA Sciences, Inc. is engaged in creating security solutions addressing the challenges of modern commerce. The company has market cap of $64.34 million. The Firm is also engaged in the large-scale production of specific deoxyribonucleic acid sequences using the polymerase chain reaction (PCR). It currently has negative earnings. The Company’s principal technology platform includes SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon.

More notable recent Applied DNA Sciences Inc (NASDAQ:APDN) news were published by: Marketwired.com which released: “Applied DNA Sciences Signs 5-Year Supply Agreement for Bulk DNA Manufacturing” on April 20, 2017, also Seekingalpha.com with their article: “Applied DNA Sciences’ (APDN) CEO James Hayward on Q1 2017 Results – Earnings …” published on February 10, 2017, Marketwired.com published: “Applied DNA Sciences Appoints Dr. Mehmood Khan to Company’s Strategic Advisory …” on January 04, 2017. More interesting news about Applied DNA Sciences Inc (NASDAQ:APDN) were released by: Businesswire.com and their article: “Applied DNA and Videojet Enter Strategic Partnership to Offer New Security …” published on September 26, 2017 as well as Seekingalpha.com‘s news article titled: “Applied DNA Sciences’ (APDN) CEO James Hayward on Q2 2017 Results – Earnings …” with publication date: May 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.